drugset / Trial / NCT00428584
RNF and Betaseron® Tolerability Study
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.
Timeline
- Start
- 2006-12
- Primary completion
- 2007-11
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon beta-1b | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | human interferon beta 1a | Unknown | 44 ug | Subcutaneous |